A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) (ENDEAVOR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04626674

Recruitment Status : Enrolling by invitation

First Posted : November 12, 2020

Last Update Posted : August 1, 2023

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborator:

Hoffmann-La Roche

Information provided by (Responsible Party):

Sarepta Therapeutics, Inc.

Study Details
Tabular View
No Results Posted
Disclaimer
How to Read a Study Record

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Enrolling by invitation
Estimated Primary Completion Date :	November 30, 2024
Estimated Study Completion Date :	July 31, 2026

To Top